About Us
Asia Air WatchLive PM2.5 Medical Alerts
Research Watch
•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs

Symptom Impact in Angelman Syndrome: Results from the Hope in Action Caregiver Survey.

Researchers

Holly L Peay, Sarah Nelson Potter, Anne C Wheeler, Jennifer Panagoulias, Niki Armstrong, Amanda Moore, Allyson Berent, Ryan Fischer

Abstract

Angelman syndrome is a rare neurological disorder with no approved disease-modifying therapies. First-generation treatments are expected to be disease modifying but not curative, highlighting the importance of understanding symptoms with the greatest impact on individuals with Angelman syndrome and their caregivers to support patient-focused drug development. The Hope in Action survey was designed to capture lived experiences and inform an externally led, patient-focused drug development meeting. A global online survey was conducted among primary caregivers of individuals with Angelman syndrome. The survey was developed by a multidisciplinary team with input from advocates, caregivers, and representatives of the US Food and Drug Administration. Caregivers ranked top-3 domains and rated related symptoms affecting individuals with Angelman syndrome and those impacting caregivers; and top-5 priority symptoms to address with a new non-curative therapeutic. Analyses were descriptive. When ranking and rating from lists of high-impact domains and symptoms, 370 caregiver participants most frequently identified communication, daily living skills, gross motor function, and cognition as impactful to individuals living with Angelman syndrome, and patients' independence and communication challenges as impactful to their own caregiver functioning, social participation, and mental health. Priority symptoms to treat with a new therapy included expressive communication, seizures, mobility, sleep, toileting, aggression, balance, and sustained attention/engagement. Through the largest caregiver-reported study on Angelman syndrome symptom impact, we demonstrate an unmet treatment need and a profound impact on individuals and caregivers across a multitude of domains. These findings directly inform patient-focused drug development and reflect alignment of caregiver priorities and outcome measure selection for trials. WHAT IS ANGELMAN SYNDROME?: Angelman syndrome (AS) affects development, cognition, communication, movement, sleep, and behavior. People with AS cannot describe their own experiences, so caregivers are critical in understanding how AS affects the individual and their family. WHY WAS THIS STUDY DONE?: We wanted to learn which symptoms have the greatest impact on people with AS and their caregivers and which were most important to treat. This information supports the development of treatments that improve symptoms that matter most to families. WHAT DID WE DO?: Three hundred and seventy caregivers completed an online survey. Caregivers ranked the top 3 groups of symptoms with the greatest impact on the person with AS and rated how much specific symptoms in those groups affected them. They then answered questions about AS impact on themselves as caregivers. Finally, they ranked the five most important symptoms to address with a new treatment. WHAT DID WE FIND?: Communication problems, challenges with everyday self-care, motor difficulties, and learning or thinking problems had the greatest impact on individuals with AS. The most difficult symptoms included minimal or absent speech and limited independence in performing self-care. Caregivers also described major effects on their own lives based on the individual with AS’ lack of independence and limited communication skills. They ranked high impact on their own social life and mental health. Priority symptoms to treat included expressive communication, seizures, mobility, sleep, toileting, aggression, balance, and sustained attention/engagement. As we intentionally asked caregivers to select among impacts and symptoms that have already been shown to be important, this study should not be interpreted to say what is not important. In fact, all of the groups and symptoms were chosen as most important by some caregivers in the survey. This shows the high unmet treatment need and the broad impact of AS on caregivers and people living with AS. WHY DOES THIS MATTER?: Our findings highlight how AS affects individuals and their families and symptoms they want addressed in a new non-curative treatment. Understanding these priorities can help ensure that new treatments deliver improvements in everyday life. The results also show how to measure outcomes in clinical trials that matter to caregivers.
Source: PubMed (PMID: 43034975)View Original on PubMed